[1] Posovszky C, Buderus S, Classen M, et al. Acute infectious gastroenteritis in infancy and childhood[J]. Dtsch Arztebl Int, 2020, 117(37): 615-624. DOI: 10.3238/arztebl.2020. 0615.
[2] Czerwionka-Szaflarska M, Łoś-Rycharska E, Gawryjołek J. Allergic enteritis in children[J]. Prz Gastroenterol, 2017, 12(1): 1-5. DOI: 10.5114/pg.2017.65677.
[3] Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family[J]. Immunol Rev, 2018, 281(1): 154-168. DOI: 10.1111/imr.12619.
[4] Griesenauer B, Paczesny S. The ST2/IL-33 axis in immune cells during inflammatory diseases[J]. Front Immunol, 2017, 8: 475. DOI: 10.3389/fimmu.2017.00475.
[5] Liew FY, Girard JP, Turnquist HR. Interleukin-33 in health and disease[J]. Nat Rev Immunol, 2016, 16(11): 676-689. DOI: 10.1038/nri.2016.95.
[6] Murdaca G, Greco M, Tonacci A, et al. IL-33/IL-31 axis in immune-mediated and allergic diseases[J]. Int J Mol Sci, 2019, 20(23): 5856. DOI: 10.3390/ijms20235856.
[7] Licari A, Votto M, D'Auria E, et al. Eosinophilic gastrointestinal diseases in children: a practical review[J]. Curr Pediatr Rev, 2020, 16(2): 106-114. DOI: 10.2174/1573396315666191022154432.
[8] Ghssein G, Salami A, Salloum L, et al. Surveillance study of acute gastroenteritis etiologies in hospitalized children in South Lebanon (SAGE study) [J]. Pediatr Gastroenterol Hepatol Nutr, 2018, 21(3): 176-183. DOI: 10.5223/pghn.2018.21.3.176.
[9] Yuan C. IL-33 in autoimmunity; possible therapeutic target[J]. Int Immunopharmacol, 2022, 108: 108887. DOI: 10.1016/j.intimp.2022.108887.
[10] Chen J, He Y, Tu L, et al. Dual immune functions of IL-33 in inflammatory bowel disease[J]. Histol Histopathol, 2020, 35(2): 137-146. DOI: 10.14670/HH-18-149.
[11] Drake LY, Kita H. IL-33: biological properties, functions, and roles in airway disease[J]. Immunol Rev, 2017, 278(1): 173-184. DOI: 10.1111/imr.12552.
[12] Chen Z, Luo J, Li J, et al. Interleukin-33 promotes serotonin release from enterochromaffin cells for intestinal homeostasis[J]. Immunity, 2021, 54(1): 151-163.e6. DOI: 10.1016/j.immuni.2020.10.014.
[13] Palmieri V, Ebel JF, Ngo Thi Phuong N, et al. Interleukin-33 signaling exacerbates experimental infectious colitis by enhancing gut permeability and inhibiting protective Th17 immunity[J]. Mucosal Immunol, 2021, 14(4): 923-936. DOI: 10.1038/s41385-021-00386-7.
[14] Xiao Y, Huang X, Zhao Y, et al. Interleukin-33 promotes REG3γ expression in intestinal epithelial cells and regulates gut microbiota[J]. Cell Mol Gastroenterol Hepatol, 2019, 8(1): 21-36. DOI: 10.1016/j.jcmgh.2019. 02.006.
[15] Hoo ZH, Candlish J, Teare D. What is an ROC curve? [J]. Emerg Med J, 2017, 34(6): 357-359. DOI: 10.1136/emermed-2017-206735.
[16] Vickers AJ, Holland F. Decision curve analysis to evaluate the clinical benefit of prediction models[J]. Spine J, 2021, 21(10): 1643-1648. DOI: 10.1016/j.spinee.2021.02.024.
|